Elizabeth H. Stover, MD, PhD, on Nivolumab and Bevacizumab: Genomic Biomarker Analysis of an Ovarian Cancer Regimen

Posted: Wednesday, September 2, 2020

Elizabeth H. Stover, MD, PhD, of Dana-Farber Cancer Institute, discusses her phase II study of treatment with nivolumab plus bevacizumab and the next steps needed to identify genomic or transcriptomic biomarkers of responses to checkpoint blockade and antiangiogenic therapy for ovarian cancer.